相关实验视频

Updated: Feb 19, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

具有ROS1阳性的非小细胞肺癌:从基因组学到治疗决策

Mylène Wespiser¹, Romane Gille¹, Maurice Pérol¹

¹Department of Medical Oncology, Centre Léon Bérard, Lyon, France.

Frontiers in oncology

|February 18, 2026

概括

在非小细胞肺癌 (NSCLC) 中的ROS1重组是可向的. 下一代TKI改善了结果,但耐药性需要分子重新评估以进行量身定制的治疗和持久的治疗.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
药理学药理学是指药理学的学科.

背景情况:

ROS1的重新排列可以确定非小细胞肺癌 (NSCLC) 的可向子集 (~2%).
这些重组通常伴有转移性疾病和中枢神经系统 (CNS) 的参与.
现有的ROS1氨酸激酶抑制剂 (TKI) 改善了结果,但面临着不可避免的耐药性.

研究的目的:

审查当前有关ROS1生物学,诊断,治疗和NSCLC中耐药机制的知识.
为管理ROS1重排的NSCLC提供以实践为导向的框架.
突出针对性治疗的进展和未来的研究重点.

主要方法:

关于NSCLC中ROS1重排的当前文献的综合.
概述ROS1的融合架构,信号和特定合作伙伴的特点.
诊断模式的总结,重点是基于RNA的下一代测序 (NGS).

主要成果:

基于RNA的NGS是融合检测和电阻分析中最敏感的方法.
穿透中枢神经系统的下一代TKI是首选的第一线疗法,在抵抗突变方面表现出有效性.
雷波特雷克提尼布,塔莱特雷克提尼布和齐德萨米提尼布表现出显著的全身和内活性.

结论:

优化测序策略,评估外科手术期间的方法和基因组监测是主要的优先事项.
进展正在改善ROS1重排的NSCLC的自然史,朝着精确驱动的范式发展.
在进展时进行分子重新评估对于指导随后的量身定制治疗至关重要.

关键词:

ROS1 的重新排列.临床试验临床试验临床试验临床试验临床试验药物耐药性耐药性药物耐药性非小细胞肺癌的肺癌.基因上的人是基因上的人氨酸激酶抑制剂氨酸激酶抑制剂

更多相关视频

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...